Navigation Links
Delcath Expands Board of Directors With Appointment of Gabriel Leung
Date:3/31/2011

–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the acceptability of the Phase III clinical trial data by the FDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales in the United States, acceptance of the Company's CE Mark Technical File by its Notified Body, receipt of CE Mark approval, adoption, use and resulting sales in the EU, if any, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, approval of the current or future chemosaturation system for other indications, actions by the FDA or other regulatory agencies, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward–looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward–looking statements to reflect events or circumstances after the date they are made.Investor Contact:

Media Contact:Gregory Gin/Doug Sherk

Janine McCargoEVC Group

EVC Group646-455-4801/415-896-6818

646-528-4034
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath to Present at Upcoming Investor Conferences
2. Delcath Systems Receives Refusal to File Letter From FDA
3. Delcath Achieves ISO 13485 Certification
4. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
5. Delcath Systems Announces Third Quarter Progress Report Conference Call
6. Delcath Strengthens Research and Development Team with Key Appointments
7. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
8. Delcath to Present at the William Blair Emerging Growth Stock Conference
9. Delcath to Present at the JMP Securities Healthcare Conference
10. Delcath Systems Announces Completion of Common Stock Offering
11. Delcath to Present at the 30th Annual Canaccord Global Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015  Valeant Pharmaceuticals International, Inc. ... closing of its previously announced registered offering of common ... (the "Offering"). Pursuant to the Offering, the Company issued ... share, for aggregate gross proceeds of approximately $1.45 billion. ... U.S. Securities and Exchange Commission a final prospectus supplement ...
(Date:3/27/2015)... DALLAS , March 27, 2015   ... global leader in biosimilars and the world,s leading ... two studies that support an evaluation of biosimilarity ... U.S. Food and Drug Administration (FDA) conditionally approved ... Amgen,s EPOGEN™ (epoetin alfa). These study data were ...
(Date:3/27/2015)... YORK , March 27, 2015  Delcath ... pharmaceutical and medical device company focused on oncology ... and metastatic liver cancers, announces the reporting of ... Company,s Melphalan Hydrochloride for Injection with the Delcath ... a poster presentation at the Society of Surgical ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
... , RICHMOND, Calif., Oct. 13 Sangamo BioSciences, Inc. ... its previously announced public offering of 3,000,000 shares of ... share. The net proceeds to Sangamo from the sale ... and commissions and other estimated offering expenses, were approximately ...
... Accuray Incorporated (Nasdaq: ARAY ), a global leader ... is scheduled to present at the Oppenheimer Healthcare Conference in ... a.m. ET (6:40 a.m. PT). , A live webcast of ... page of the Company,s Web site at http://www.accuray.com ...
Cached Medicine Technology:Sangamo Announces Closing of Common Stock Offering 2Sangamo Announces Closing of Common Stock Offering 3Accuray Incorporated to Present at 20th Annual Oppenheimer Healthcare Conference 2
(Date:3/28/2015)... (PRWEB) March 28, 2015 Delaying rotator ... be necessary, according to research presented today at the ... Specialty Day. , “Our study compared results for 170 ... underwent an additional glenohumeral joint capsule release procedure to ... Murrell MD, PhD, lead author from St. George Hospital ...
(Date:3/28/2015)... Genomic medicine experts have sequenced the genomes ... first time, key information for understanding and treating this ... posted story on the Surviving Mesothelioma website. ... the British Columbia Cancer Agency, and PhenoPath lab in ... alterations and mutations that can lead to peritoneal ...
(Date:3/28/2015)... 2015 Lately the student-athlete experience ... changes and proposals around the NCAA. In a March ... collegiate student-athletes across a spectrum of universities and sports ... challenges. The special panel consists of athletes who have ... from football, track and field, baseball, and volleyball. They ...
(Date:3/28/2015)... La Mirada, CA (PRWEB) March 28, 2015 ... with ear, nose and throat disorders, are ... Tinnitus is a common issue which is characterized by ... ears. Affecting 1 in 5 people, tinnitus is a ... or disorder and while it is non-fatal, tinnitus can ...
(Date:3/28/2015)... 2015 Designers and Professionals of ... Scratches 5K from Pixel Film Studios. , “Scratches 5K ... media inside Final Cut Pro X” Said Christina Austin, ... and is an effective tool for any FCPX editor.” ... 5K's intuitive grunge overlays. Simply drag title layers into ...
Breaking Medicine News(10 mins):Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2
... , , , ... , LOUISVILLE, Ky., July 23 University of Louisville physicians ... Hospital in Louisville, KY, on July 17, 2009. The procedure is part ... treat heart disease. , , ...
... SAN DIEGO, July 23 Orexigen Therapeutics, Inc. ... priced an underwritten public offering of 10,000,000 shares of its ... proceeds, after estimated underwriting discounts and commissions and estimated expenses, ... a 30-day option to purchase up to an additional 1,500,000 ...
... Ohio, July 23 Estimates place the prevalence of physical ... of the global adult population according to THE ORTHOPAEDIC ... , , "Our sources indicate ... increased 25 percent over the past ten years, and those ...
... DENVER, CO, July 23 /PRNewswire-FirstCall/ - Medical International Technology ... is pleased to announce that it has been granted ... per "MIT China" requirements, from the "China Medical City" ... half years. , The operation facility will harbor all ...
... , , , ... TELEHOUSE America ( www.telehouse.com ) ... exchanges, and managed IT services, today announced it is offering ... prevention (DLP) consulting services as part of its Manage-E ...
... , , , ... Media, LLC., a new media and publishing company, today announced the ... a weekly web digest devoted to covering the ideas, technologies, business ... on opportunities for progress in healthcare, Healthspottr delivers select, forward-thinking content ...
Cached Medicine News:Health News:Orexigen(R) Therapeutics Prices Public Offering of Common Stock 2Health News:THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT Highlights the Burgeoning Demographics of Orthopaedics and the Continuing Health of the Industry 2Health News:MIT granted an 8,000 square foot operation facility in Taizhou city for a period of 2 and half years 2Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 2Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 3Health News:TELEHOUSE America Offers Integralis' Data Loss Prevention Consulting Services as Part of its Manage-E Solution 4Health News:Introducing Healthspottr: The New Voice of Healthcare Innovation 2Health News:Introducing Healthspottr: The New Voice of Healthcare Innovation 3
Operate with confidence. Autosuture is advancing the sate of both open and minimally invasive surgery by providing surgical tools that feel right, function right, and facilitate the right outcome eve...
... Many special order products are offered ... extra long lengths. The modular instruments may ... other options such as ratchets, insulation and ... from Mediflex stock. Customer specifications may affect ...
... Many special order products are offered as ... long lengths. The modular instruments may be ... options such as ratchets, insulation and flush ... Mediflex stock. Customer specifications may affect delivery ...
... order products are offered as 1-piece or ... The modular instruments may be customized with ... as ratchets, insulation and flush ports. Many ... Customer specifications may affect delivery times. ...
Medicine Products: